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INTRODUCTION
Biobanks1 have emerged as a significant research tool, gaining support from both the
scientific community and regional, national and international research funding agen-
cies. However, developing and maintaining these platforms is expensive. Indeed, in a
recent survey of operational personnel representing 456 biobanks, funding shortages
concerned 71% of those surveyed and 37% identified ‘funding’ as ‘the biobank’s great-
est challenge.’2Thus, unsurprisingly, biobanksmay seek support from theprivate sector
or philanthropic organizations, which have an interest in sustaining them as research
resources.
The scientific community is also increasingly facing pressure to commercialize and
translate their work, thus increasing expectations of industry partnerships.3 Funding
agencies, in part, create and reinforce this commercialization pressure, by earmarking
grants for projects that aim to bring products and therapies to themarket within a short
amount of time.4 This commercialization process creates a range of policy challenges
for scientists, research participants, and funders.
The goal of this document is to outline the policy issues associated with the com-
mercialization of biobanks and, where possible, to review the relevant evidence and/or
1 While there is no general consensus on an exact definition of the term ‘biobank’, we adapt the definition pro-
vided by the Public Population Project in Genomics and Society: ‘[a]n organized collection of human biolog-
ical material and associated information stored for one or more research purposes’: Public Population Project
in Genomics and Society (P3G), biobank lexicon, http://www.p3g.org/biobank-lexicon; Gail E. Henderson
et al.,Characterizing BiobankOrganizations in the US: results from aNational Survey, 5GenomeMed. 3 (2013).
As Henderson and colleagues note, biobanks come in a wide variety of forms, with significant differences in
organizational and funding structures, diversity in research goals and specimen collections, and variation in
partnerships with other organizations (such as universities or research centers): Id. The issues raised in this
paper may be relevant to both general biobanks and population biobanks (a collection of biological materials
that: ‘has a population basis’; ‘is established, or has been converted, to supply biological materials or data de-
rived therefrom for multiple future research projects’; ‘contains biological materials and associated personal
data which may include or be linked to genealogical, medical or lifestyle data and which may be regularly up-
dated’; and ‘receives and supplies materials in an organized manner’): Council of Europe Committee of Min-
isters, Recommendation Rec(2006)4 of the Committee ofMinisters tomember states on research on biologi-
cal materials of human origin, https://wcd.coe.int/ViewDoc.jsp?id=977859. See also, BarthaM. Knoppers et
al., Sampling Populations of Humans across the World: ELSI Issues, 13 Annu. Rev. Genomics Hum. Genet. 395
(2012).
2 R. Jean Cadigan, Neglected Ethical Issues in Biobank Management: results from a US Study, 9 Life Sci. Soc. Pol.
1 (2013). See also, Henderson, supra note 2. It is also worth noting that Caulfield was approached by sev-
eral Canadian biobank initiatives, including the province of Alberta’s CBCF Tumor Bank and the Canadian
Health Infant Longitudinal Development (CHILD) Study, about the issues associated with commercializa-
tion. Indeed, these communications helped to justify the production of this article.
3 TimothyCaulfield,CommercializationCreep, Pol.Options20 (2012);TaniaM.Bubela andTimothyCaulfield,
Role andReality: technologyTransfer atCanadianUniversities, 28TrendsBiotechnol. 447 (2010);C.J.Murdoch
andTimothyCaulfield,Commercialization, Patenting andGenomics: researcher Perspectives, 1 GenomeMed. 22
(2009);ManuelCrespo andHoussineDridi, Intensification ofUniversity—Industry Relationships and Its Impact
on Academic Research, 54 High Educ. 61 (2007); Francis S. Collins, Reengineering Translational Science: the
Time is Right, 3 Sci. Transl. Med. 90cm 17 (2011); Elias A. Zerhouni et al.,The Biomarkers Consortium: public
and Private Sectors Working in Partnership to Improve the Public Health, 12 Oncologist 250 (2007); Timothy
Caulfield, Sustainability and the Balancing of the Health Care and Innovation Agendas: the Commercialization of
Genetic Research, 66 Sask. Law Rev. 629 (2003).
4 Timothy Caulfield, Patents or Commercialization Pressure? A (Speculative) Search for the Right
Target, 22 J. Law, Information And Science 122 (2012); Genome Canada, 2012 Large-Scale
Applied Research Project Competition, http://www.genomecanada.ca/en/portfolio/research/
2012-competition.aspx (accessed 30 January 2014).
96  A review of the key issues associated with the commercialization of biobanks
ethical and legal norms.5 We do not attempt to provide suggestions for policy reform.
Nevertheless, given that securing funding for biobanks remains a challenge and that re-
searchers are increasingly pressured to work with industry and to rapidly translate their
work, a scoping document of this nature—one that draws together international ex-
pertise and relevant research—seems timely and, we hope, can stand as a resource for
future research and policy work.
‘Commercialization’ can refer to a number of different activities. It can refer to the
commercializationof biobank resources (dataor samplesof humanbiologicalmaterial)
or of research results derived or products developed from those resources. It can also
refer to publicly funded biobanks partnering with or receiving funding from private,
for-profit entities like biotech companies, pharmaceutical corporations, or the medi-
cal device industry. For the purposes of this scoping document, we will largely focus
on the introduction of private funding and partnerships to an existing, publicly funded
biobank.This focus is justified becausemany biobanks are not-for-profit entities associ-
ated with larger (often publicly-funded) bodies, such as universities and hospitals, and
funded, often through short-term grants, by these bodies, by the government, or by a
mixture of public and private funds.6 Survey evidence indicates that these biobanks are
greatly concernedwith securing adequate long-term funding.7 AsMeijer andcolleagues
note, with the expansion and change in the size, goals and structure of biobanks, ‘stable
sources of core funding will be necessary in most cases, from the public sector, patient
organizations and private foundations.’8 Given this reality, we believe that commer-
cialization will particularly and uniquely impact publicly supported biobanks, as they
consider various means, including private partnerships, to ensure financial security.9
Of course, biobanks vary greatly in organization, priorities, and funding,10 and thus
commercialization will affect different biobanks in different ways. Not every biobank
will seek commercial partnerships in response to financial pressures, and, indeed, delin-
eating which factors (eg type of biobank; organizational structure; research goals and
focus) influence the development of private partnerships may be an important ques-
tion for future research. Indeed, we hope this overview of issueswill inform these future
funding decisions.
In addition to our primary focus on the introduction of private financing and part-
nerships, some of the emerging research and commentaries on the issues associated
with commercialization are relevant to a range of other activities and are worth con-
sidering here. For example, issues of public trust can be triggered by a variety of
5 While there are, no doubt, a number of intellectual property issues relevant to this area, we will not address
them in this paper (egAssociation for Molecular Pathology versus Myriad Genetics Inc., 133 S. Ct. 2107 (2013)).
6 Henderson, supra note 2; IngeborgMeijer, Jordi Molas-Gallart and PaulineMattsson,Networked Research In-
frastructures and their Governance: the Case of Biobanking, 39 SPP 491 (2012).
7 Henderson, supra note 2; Cadigan, supra note 3; Aaro Tupasela andNeil Stephens,TheBoom and Bust Cycle of
Biobanking—ThinkingThrough the Life Cycle of Biobanks, 54.5 Croat. Med. J. 501 (2013); Mylene Deschenes
et al., Intellectual Property Rights in Publicly Funded Biobanks: much Ado about Nothing? 29.4 Nat. Biotechnol.
319 (2011); Meijer, supra note 7.
8 Meijer, supra note 7, at 496.
9 Whilewedonot have empirical data on the number of public biobanks seeking private partnerships, we suggest
that this important question could be the subject of research in the future.
10 Henderson, supra note 2.
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commercialization practices, as we will see. Thus, where appropriate, we will discuss
commercialization activities beyond just the introduction of private funding.
Before turning to the issues at hand, it may be useful to set out some of the scenarios
in which commercialization may occur. In this paper, as noted, we largely concentrate
on the introductionof private funding to apre-existingpublicly fundedbiobank. In such
a case, a chief concern for the biobank will be retaining participants who were, presum-
ably, originally recruited with an understanding that the biobank would be a ‘public
good.’ In this case, issues related to consent, participant retention, and withdrawal of
biological material and associated data are particularly important. We can contrast this
with a scenario in which the biobank is a public-private partnership from its inception.
In such as case, enrollment of participants and obtaining consent to commercial imper-
atives, if any, are likely to be the prime focuses of the biobank. The different situations
of these biobanks may inform and nuance the discussion that follows.
Issues
Public Trust and Public Expectations
Trust is critical in determining whether people will participate in and support biobank-
ing research. Public trust and how it influences the public’s support for science is com-
plex and influenced by many factors, including perceptions of the actors and institu-
tions involved in research.11 There is little doubt that the general public places a good
deal of trust in the university-based scientific community. For example, a 2013 survey
of United Kingdom residents commissioned by the Wellcome Trust found that 66%
percent of respondents completely trusted or had a great deal of trust in university sci-
entists.12 However, it also showed that trust evaporated quickly if scientists worked for
either industry (trusted by 32% of respondents) or government (trusted by 34% of re-
spondents).13 This has also been the case in Australia, where the Swinburne National
Technology and SocietyMonitor has consistently found high public trust in scientists,
universities and government research organizations.14 Trust in public research institu-
tions remains high even for controversial medical research (including some research in
genetics), but decreases significantly with industry involvement.15
11 David B. Resnik, Scientific Research and the Public Trust, 17 Sci. Eng. Ethics 399 (2011); Zubin Master and
David B. Resnik,Hype and Public Trust in Science, 19 Sci. Eng. Ethics 321 (2013). ‘Public trust’ is not a static
or easily quantifiable concept. Rather, it is relational, ongoing, and changing. Additionally, as we discuss be-
low, the ‘public’ is not a homogenous entity that speaks with one voice: there are many different groups that
comprise ‘the public’, and these groups may differ in their trust of scientists. These relationships of trust may
be affected by a number of different factors and change at different periods of time.
12 Michael Clemence et al., Wellcome Trust Monitor Wave 2: Tracking Public Views on Science, Biomedical
Research and Science Education (London, UK 2013).
13 Id.
14 The Swinburne National Technology and Society Monitor (proposed 30 July 2012), http://www.
swinburne.edu.au/lss/spru/spru-monitor.html.
15 Christine Critchley and Lyn Turney,Understanding Australians’ Perceptions of Controversial Scientific Research,
2 AJETS 82 (2004); Christine R. Critchley and Dianne Nicol,Understanding the Impact of Commercialization
on Public Support for Scientific Research: is It About the Funding Source or the Organization Conducting the Re-
search, 20 Public Underst. Sci. 347 (2011).
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The involvement of industry in research seems to have considerable influence on
public trust in science, irrespective of the type of research.16 This holds true in the
biobanking context, aswell. Several studies show thatmanyparticipants have a negative
attitude towards the involvement of commercial entities in biobanks and biobanking
research.17 A survey of 1,201 Albertans found that public trust in biobanking research
decreases substantially if industry is involved: 45.1% of those surveyed indicated they
had ‘a great deal’ of trust in university-funded scientists; 19.5%had ‘a great deal’ of trust
in university scientists funded by industry; and only 6% had similar trust in biobanking
research conducted by for-profit industry.18 A recent public opinion study of cancer pa-
tients similarly showed that 40.4% of participants reported having ‘a great deal’ of trust
in biobanking research performed by government-funded university researchers as
opposed to 16.3% and 3.2% of respondents reporting ‘a great deal’ of trust in industry-
funded university research and research conducted by industry, respectively.19 Inter-
estingly, a study by Critchley and Nicol suggests that the type of organization (eg
private entity versus university) has a greater impact onpublic trust than funding source
(eg private versus public funding), though the source of funding also influences pub-
lic trust.20 Though their study was not specific to biobanking research, it may suggest
that public biobankswhich receive private fundingwill be better able tomaintain public
trust than those that are completely privately owned.
Many factors may account for a negative view of private investment in public
biobanks. For instance, there is some evidence that members of the public fear that
their donated biological samples and associated health data will be used in ways they
findmorally problematic, such as in research thatmaybe stigmatizing or discriminatory
to them and/or their communities21 (for example, research connecting mental health
with racial or ethnic background). Some biobank participants fear losing control over
how their samples and data are used and with whom they are shared, and this fear may
be heightened when for-profit companies invest in publicly funded biobanks. This no-
tion is manifested in recent research by Critchley, Nicol, Otlowski and Chalmers (un-
published manuscript), which found that concern about sharing of genetic data with
private entities was the chief reason for the significant erosion of support when genetic
16 Gillian Haddow et al., Tackling Community Concerns About Commercialisation And Genetic Research: a Modest
Interdisciplinary Proposal, 64 Soc. Sci.Med. 272 (2007); Christine R. Critchley,Public Opinion andTrust in Sci-
entists:The Role of the Research Context and the PerceivedMotivation of StemCell Researchers, 17 Public Underst.
Sci. 309 (2008); Christine R. Critchley et al.,The Impact of Commercialization on Public Perceptions of StemCell
Research: Exploring Differences Across the Use of Induced Pluripotent Cells, Human and Animal Embryos, 9 Stem
Cell Rev. 541 (2013); Alan Petersen, Securing Our Genetic Health: Engendering Trust in UKBiobank, 27 Sociol.
Health Illn. 271 (2005).
17 Tore Nilstun and Go¨ran Hermere´n, Human Tissue Samples and Ethics–Attitudes of the General Public in Swe-
den to Biobank Research, 9 Med. Health Care Philos. 81 (2006); Timothy Caulfield et al., Biobanking, Consent,
and Control: a Survey of Albertans on Key Research Ethics Issues, 10 Biopreserv. and Biobank. 433 (2012); Zu-
bin Master et al., Cancer Patient Perceptions on the Ethical and Legal Issues Related to Biobanking, 6 BMCMed.
Genomics 8 (2013); A.A. Lemke et al., Public and Biobank Participant Attitudes Toward Genetic Research Par-
ticipation and Data Sharing, 13 Public Health Genomics 368 (2010); Susan Brown Trinidad et al., Genomic
Research andWide Data Sharing: Views of Prospective Participants, 12 Genet. Med. 486 (2010).
18 Caulfield et al., supra note 18.
19 Master et al., supra note 18.
20 Critchley and Nicol, supra note 16.
21 Lemke et al., supra note 18; Trinidad et al., supra note 18.
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tests were conducted by a private company compared to those controlled by the public
health care system.22
The public generally supports biobanking research,23 though the terms on which
people will participate and the expectations they have regarding participation are not
uniform and differ on keymatters like benefit sharing.24 Some people participate for al-
truistic reasons,without expecting anybenefits in return.25 Otherpeople aremore likely
to participate in biobanking research if they believe that biobanks will produce bene-
ficial results for future patients and society.26 Some participants do expect to receive
something in return, includingmonetary reward, reduced costs of the (potential) clini-
cal benefits derived from biobanking research, or the return of research results.27 These
observations also seem connected with the idea that private interests, including the
introductionof industry funding,may limit sharingof biologicalmaterial andassociated
data, prevent results from being returned, or limit public access to health benefits de-
rived from private or proprietary research.The belief that public access to benefits will
be reduced has been found to be an important reason for the decrease in public sup-
port for industry-based medical research (relative to publicly funded researchers).28
This finding, combined with the public’s desire for biobanks to share results and ad-
vance health care, suggests that some sort of benefit sharing arrangement or return of
benefits back to the community may help the public accept the commercialization im-
perative.29 Involvement of commercial entities, in the formof financial support for pub-
lic biobanks, thus has the potential to change the motivations and expectations of the
general public, hence altering the relationship between participants and biobanks. Of
course, the particular way in which financial support from industry will affect this rela-
tionship and related motivations and expectations depends on many factors and may
differ between distinct groups within the public.
The hype from genomics generally redounds to biobanks and this too might im-
pact public expectations, such as the belief that biobanks will result in benefits in the
near future.30 If the benefits of biobanking are seen to be oversold, the involvement
of commercial entities in the form of financial support is likely to garner even greater
22 Christine Critchley, Dianne Nicol, Margaret Otlowski et al., Public Reaction to Direct to Consumer Online Ge-
netic Tests: Comparing Attitudes, Trust and Intentions across Commercial and Conventional Providers (unpub-
lished manuscript).
23 Kieran C. O’Doherty et al., Involving Citizens in the Ethics of Biobank Research: Informing Institutional Policy
Through Structured Public Deliberation, 75 Soc. Sci. Med. 1604 (2012).
24 Dianne Nicol and Christine Critchley, Benefit Sharing and Biobanking in Australia, 21 Public Underst. Sci. 534
(2012).
25 Id.
26 Christine R. Critchley et al., Predicting Intention to Biobank: a National Survey, 22 Eur. J. Public Health 139
(2012); Nicol and Critchley, supra note 25; Asa Kettis-Lindblad et al.,Genetic Research and Donation of Tissue
Samples to Biobanks. What Do Potential Sample Donors in the Swedish General Public Think? 16 Eur. J. Public
Health 433 (2006).
27 Herbert Gottweis et al., Connecting the Public with Biobank Research: Reciprocity Matters, 12 Nat. Rev. Genet.
738 (2011).
28 Critchley, supra note 17; Critchley et al., supra note 17.
29 Haddow et al., supra note 11. See also Alexander Morgan Capron, Ethical Norms and the International Gover-
nance of Genetic Databases and Biobanks: Findings from an International Study, 19 Kennedy Inst. Ethic. J. 101
(2009).
30 James P. Evans et al.,Genomics. Deflating the Genomic Bubble, 331 Science 861 (2011).
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suspicion.31 The expectation that public investment should yield results for the public
good can be used to justify the creation of publicly funded biobanks and also the adop-
tion of a range of biobanking policies that may be ethically or legally contentious (eg
the use of a general or broad consent approach).32The involvement of industry can cre-
ate questions about the degree to which the biobank research is being done solely—or
even primarily—for the public good, thus compromising, in the eyes of the public, the
validity of the justification for the adoption of these policies.
It seems reasonable to think that if the public perceives scientists from private re-
search organizations to be more self-interested (ie for profit) than interested in the
public good, this could diminish trust in biobanks that previously involved only pub-
licly funded scientists, and thus hinder public participation. Yet this simple calculus has
several limits. First, a sweeping statement that all public institutions are more trust-
worthy and private ones have motives contrary to the public good is a glaring over-
simplification. Although we have referred to research which suggests that government-
funded scientists are perceived to be more trustworthy than those working in private
industry, there is an underlying distrust of the government as an overseer of biobanking
practices.33
Second, trust in actors and institutionsdiffers betweenvarious groups andmaybe in-
fluenced by factors such as race, gender, education, political or other ideology, religion,
geography, and whether the individuals in question are impacted by a disease.34 How-
ever, some evidence suggests that demographic factors have little impact onbiobanking
preferences and should not be viewed as determinative of peoples’ biobanking prefer-
ences.35
Third, not everyone will reject participating in a biobank that has some commercial
elements. Studies suggest that patient groups tend to bemore accepting of pharmaceu-
tical involvement than other civic groups, for example, and participantsmay bemore at
easewith commercialization elements if itmeans the biobank is ‘governed or regulated’
appropriately.36 Additionally, not all ‘private’ actors are seen identically and not all
‘public’ sources are deemed trustworthy. The actual governance and operations of the
biobank, whether it is partly or fully privately (ie pharmaceutical, philanthro-capital)
31 Jamie Doward, Sale of personal gene data condemned as ‘unethical and dangerous’, The Guardian, http://www.
theguardian.com/science/2013/feb/17/gene-genetic-database-nhs-genewatch (accessed 17 February
2013).
32 Timothy Caulfield, Biobanks and Blanket Consent: The Proper Place of the Public Good and Public Perception
Rationales, 18 King’s Law J. 209 (2007).
33 Lemke et al., supra note 18; Master et al., supra note 18; Trinidad et al., supra note 18; Caulfield et al., supra
note 18; ZubinMaster andDavid BResnik, Incorporating Exclusion Clauses in Informed Consent for Biobanking,
22 Camb. Q. Healthc. Ethic. 203 (2013).
34 JenniferHochschild et al., TechnologyOptimismorPessimism:HowTrust in Science Shapes PolicyAttitudes
Toward Genomic Science (Issues in Technology Innovation, Washington, DC 2012); Michael Siegrist,The
Influence of Trust and Perceptions of Risks and Benefits on the Acceptance of Gene Technology, 20 Risk Anal. 195
(2000); Linus Johnsson et al., Patients’ Refusal to Consent to Storage and Use of Samples in Swedish Biobanks:
cross Sectional Study, 337BMJ a345 (2008);Caulfield et al., supra note 18; JuliMurphy et al.,Public Perspectives
on Informed Consent for Biobanking, 99 Am. J. PublicHealth 2128 (2009);Heather L.Walmsley, StockOptions,
Tax Credits or Employment Contracts Please!The Value of Deliberative Public Disagreement About Human Tissue
Donation, 73 Soc. Sci. Med. 209 (2011).
35 Critchley and Nicol, supra note 16.
36 Kristin Solum Steinsbekk et al.,We’re Not in It for the Money-Lay People’s Moral Intuitions on Commercial Use
of ‘Their’ Biobank, 16 Med. Health Care Philos. 151 (2013); Haddow et al., supra note 17.
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or publicly (ie government, non-governmental, or government-legal) funded, and the
nature and goals of the biobank likely influence individual perceptions of trust.37
Although considerable efforts have been made to understand the attitudes of the
general public, patients, and other groups, and assess their willingness to participate in
biobanking initiatives, more research is needed especially as it relates to the involve-
ment of commercial entities in biobanking, in the form of financial support or access
by privately-funded scientists to biobank resources.38 Future research could focus on
determining the perceived aspects of commercial involvement in biobanking that affect
public trust (eg losing control over samples, misuse of biological samples and data, lim-
ited access to thebenefits of research, the returnof results, increased secrecy and limited
sharing, and research misconduct and undertaking unethical research).39 Participants
may lack knowledge about biobanking and commercialization anddesire to receive fur-
ther information. If public communication and engagement are provided, will this lead
to greater acceptance of commercial involvement in publicly-funded biobanks? And if
so, under which conditions will the general public accept various types of commercial
involvement in publicly funded biobanks? Further research could also explore whether
and how the introduction of private funding or partnerships impacts the weighing of
values and preferences that factor into an individual’s decision about whether to partic-
ipate in biobanking research.40 By identifying how public trust is affected by different
commercializationpractices, future scholarship can simultaneously focuson the related
issue of how to build or increase trust in public biobanks that partner with private en-
tities. It may be, for example, that certain approaches to public-private partnerships—
such as arrangements for benefit sharing—or actions by private entities—such as pro-
viding transparent information about intentions and goals and implementing open
communication policies—will minimize the erosion of public trust that may accom-
pany commercialization.
The current lack of consensus on many key biobanking issues41 combined with
strong public reactions to recent controversies relevant to biobanking, albeit in a dif-
ferent context (eg Havasupai Tribe versus Arizona Board of Regents; destruction of
5million blood samples byTexasDepartment of StateHealth Services), should remind
37 Eric M.Meslin et al.,Health-Related Philanthropy: toward Understanding the Relationship between the Donation
of the Body (and Its Parts) and Traditional Forms of Philanthropic Giving, 37NVSQ44S (2008); Trinidad et al.,
supra note 18.
38 Existing public perception studies have focusedmainly on exploring the views of the general public and patient
populations respecting involvement of commercial partners in biomedical research and biobanking. This has
created a gap in our understanding of the views of a range of other stakeholders including scientists, biobank
personnel, public officials, regulators, and investors. Surveying the perspectives of scientists, for example, will
provide knowledge about how those who conduct this research view commercialization and whether they see
any ethical or practical problems arising from industry involvement. It may be, for example, that scientists
who collect biobank samples anticipate ‘first right of access’ to the samples for research purposes and fear that
private funding or granting access to industry researchers will create barriers.
39 Elizabeth J. Horn et al.,Engaging Research Participants and Building Trust, 15Genet. TestMol. Biomarkers 839
(2011).
40 A study by Pullman and colleagues examined the value rankingmade by the public when considering whether
to participate in biobanking research, but did not specifically look at whether this ranking would be affected
by the involvement of private, for-profit companies (Daryl Pullman et al., Personal Privacy, Public Benefits, and
Biobanks: a Conjoint Analysis of Policy Priorities and Public Perceptions, 14 Genet. Med. 229 (2012)).
41 ZubinMaster et al., Biobanks, Consent and Claims of Consensus, 9 Nat. Methods 885 (2012).
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us that trust can easily sway and may have a profound impact on biobanking endeav-
ors.42
Conflicts of Interest
Commercialization may result in tension between the interests of private partners and
those of the researchers or organizers of the biobank, which raises a number of inter-
related concerns. If commercial entities contribute funding for biobanking research,
scientists ‘may relinquish part of their independence over the development of the
research.’43 Or procuring private investment or promoting the interests of commercial
partners may trump other interests or priorities.44 For example, a biobank might au-
thorize secondary uses of data or samples that either risk misuse of the resource or are
inconsistent with the consent of participants in order to secure private funding. Like-
wise, scientists may replace basic, essential research with commercially-profitable re-
search.45 Similarly, commercialization in the form of financial relationships between
private entities and university scientists could compromise research integrity.46 For
example, studies in other fields of biomedical research have shown that ‘industry-
sponsored research tends to draw pro-industry conclusions.’47 Public perception of
biomedical science as a tool for the ‘public good’ may be negatively impacted by these
outcomes.48 As Hoeyer observes, ‘commercial incentives might work contrary to the
ambition of using stored tissue to address public health problems, both by impeding
some research collaborations and by modifying the research agenda and our shared
understanding as to what constitutes an important health problem.’49
Consent
The issue of consent has proven to be one of the most divisive topics in the context of
biobanking research. High profile tissue banking and genomic research cases—albeit
not involving publicly funded population biobanks—and subsequent media attention
42 Michelle M. Mello and Leslie E. Wolf,The Havasupai Indian Tribe Case–Lessons for Research Involving Stored
Biologic Samples, 363N. Engl. J. Med. 204 (2010); Jay Root,Texas officials agree to destroy babies’ blood samples
after settling lawsuit, DALLAS MORNING NEWS (proposed 26 November 2010) http://www.dallasnews.com/
news/state/headlines/20091223-Texas-officials-agree-to-destroy-babies-1751.ece; Havasupai Tribe versus
Arizona Board of Regents, 204 P.3d 1063, 220 Ariz. 214 (Ct. App. 2008). See also Ricki Lewis, Is
the Havasupai Indian Case a Fairy Tale?, Plos Blogs (proposed 15 August 2013) http://blogs.plos.
org/dnascience/2013/08/15/is-the-havasupai-indian-case-a-fairy-tale.
43 Mahsa Shabani, Heidi CarmenHoward and Pascal Borry,Commercialization of Population Biobanks: in Search
of Lost Trust? (unpublished manuscript).
44 Id.
45 Ann Silversides,Merchant Scientists, THEWALRUS, May 2008.
46 Justin E. Bekelman et al., Scope and Impact of Financial Conflicts of Interest in Biomedical Research: a Systematic
Review, 289 JAMA 454 (2003); Joel Lexchin et al., Pharmaceutical Industry Sponsorship and Research Outcome
andQuality: systematic Review, 326BMJ1167 (2003);MohitBhandari et al.,AssociationBetween Industry Fund-
ing and Statistically Significant Pro-Industry Findings inMedical and Surgical Randomized Trials, 170 CMAJ 477
(2004).
47 Bekelman et al., supra note 47.
48 Shabani, supra note 44.
49 Klaus Hoeyer, Trading in Cold Blood?, in TRUST IN BIOBANKING: DEALING WITH ETHICAL, LEGAL AND SOCIAL
ISSUES IN AN EMERGING FIELD OF BIOTECHNOLOGY 21 (2012).
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surrounding these cases highlight the sensitivity of the consent issue and may con-
tribute to increased scrutiny of biobanking practices.50
Consent issues typically arise in connection with the down-stream commercializa-
tion of products and therapies derived from research on biobank samples and data.
Informed consent laws and norms require that researchers inform participants about
potential commercial uses of their biological samples and data. But consent issues also
emerge when considering the introduction of financial support by private entities to
public biobanks, particularly if this possibility had not been addressed in the initial
consent.
The importance of informing research participants about potential commercial ap-
plications resulting from research on their samples and data—an inevitable byproduct
of industry involvement—has been endorsed by numerous guidelines and recommen-
dations.51 Disclosure is required, in part, because knowledge of potential commercial
uses has been shown to be a relevant factor in the decision of individuals to participate
in biomedical research. As noted above, studies52 have reported that participants may
see commercial applications at odds with their initial reasons for and expectations re-
garding participation.53 It is an ethical imperative that scientists be transparent regard-
ing intended commercial use and address participants’ concerns related to commercial-
ization.54 Again, depending on the nature of the commercialization agreements, these
kindsof concernsmaybe anatural consequenceof industry fundingof apublic biobank.
50 Rebecca Skloot,The Immortal Life of Henrietta Lacks, the Sequel, THE NEW YORK TIMES, (proposed 23 March
2013) http://www.nytimes.com/2013/03/24/opinion/sunday/the-immortal-life-of-henrietta-lacks-the-
sequel.html; Mello and Wolf, supra note 43; Havasupai, supra note 43. Henrietta Lacks’s family and the
National Institutes of Health (NIH) subsequently reached an agreement which provides for the disclosure
of the genomic data through a ‘controlled access’ mechanism: Kathy L. Hudson and Francis S. Collins,
Biospecimen Policy: family Matters, 500 Nature 141 (2013). See also Timothy Caulfield and Amy L. McGuire,
Policy Uncertainty, Sequencing, and Cell Lines, 3 Genes, Genome and Genetics (G3) 1205 (2013).
51 HUGO Ethics Committee, Statement on Human Genomic Databases (2002) http://www.hugo-
international.org/img/genomic 2002.pdf; Organization for Economic Co-Operation and Devel-
opment, OECD Guidelines on Human Biobanks and Genetic Research Databases (OECD Pub-
lishing 2009) http://www.oecd.org/sti/biotech/44054609.pdf; Canadian Institutes of Health
Research et al., Tri-Council Policy Statement: ethical Conduct for Research Involving Humans (2010),
http://www.ethics.gc.ca/pdf/eng/tcps2/TCPS 2 FINAL Web.pdf; European Society of Human Genetics,
Data Storage and DNA Banking for Biomedical Research, 11 Eur. J. Hum. Genet. S8 (2003).
52 John-Arne Skolbekken et al.,Not Worth the Paper It’s Written on? Informed Consent and Biobank Research in a
Norwegian Context, 15 Critical Public Health 335 (2005); Be´atrice Godard et al., Community Engagement in
Genetic Research: results of the First Public Consultation for the Quebec CARTaGENE Project, 10 Community
Genet. 147 (2007);Nilstun andHermere´n, supra note 18;Haddow et al., supra note 17; Kettis-Lindblad et al.,
supra note 27.
53 Caplan,ArthurL.,WhatNoOneKnowsCannotHurt You: theLimits of InformedConsent in theEmergingWorld of
Biobanking, inTheEthics of ResearchBiobanking 25 (Springer 2009);RobertMitchell andCatherineWaldby,
National Biobanks: clinical Labor, Risk Production, and the Creation of Biovalue, 35 Sci. Technol. HumanValues
330 (2010); Klaus Hoeyer,The Role of Ethics in Commercial Genetic Research: notes on the Notion of Commodi-
fication, 24 Med. Anthropol. 45 (2005).
54 Sigrid Sterckx et al., ‘Trust is Not Something You Can Reclaim Easily’: patenting in the Field of Direct-to-Consumer
Genetic Testing, 15 Genet. Med. 382 (2013); Hoeyer, supra note 50.
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Given the increasingly common use of ‘broad consent’55 by biobanks, there may be
questions about the sufficiency of consent if commercialization plans and goals are not
clarified at the outset.Many ‘broad consents’ forms in current usemay refer,with legally
sufficient specificity, to possible future commercial applications or industry involve-
ment. However, if commercialization issues are not addressed, engaging a private en-
tity post-original consentmay necessitate a re-consent process.56 In addition, an overly
broad or generic reference to future commercialization activities may be insufficient. It
has been argued, for example, that obtaining a broad consent to use samples for a wide
range of commercial and non-commercial research in the future may be legally prob-
lematic and may require the provision of more detailed information about the nature
of the commercial activity.57
Although informed consent is a mechanism for protecting participants’ interests
and promoting their autonomy, it has limitations.58 Consent procedures need to be
coupled with other governance mechanisms, such as ongoing monitoring by oversight
committees, in order to ensure that biobank resources will be put to the best possible
uses.59 Prior consultation and communication with communities and interest groups
should also be considered.60 As Luther and Lemmens note, ‘an over-emphasis on con-
sent, without sufficient attention to societal, economic, structural and other challenges
to individual decision-making, may undermine rather than protect the interest of in-
dividuals’.61 As such, any consent mechanism or process that is put in place to address
55 Under broad consent approaches, participants may give their consent to a range of future research uses of
their biological material and data, though the specific nature of these future research uses is not known at the
time consent is given. In contrast, specific consent mandates that researchers obtain consent for each new and
distinct research project (Carlo Petrini, ‘Broad’ Consent, Exceptions to Consent and the Question of Using Biolog-
ical Samples for Research Purposes Different from the Initial Collection Purpose, 70 Soc. Sci. Med. 217 (2010)).
While broad consent remains controversial in academic literature, ethical guidelines, and amongst the gen-
eral public, it dominates biobank practice: Master et al., supra note 42. See also Clarissa Allen, Yann Joly and
Palmira Granados Moreno, Data Sharing, Biobanks and Informed Consent: a Research Paradox?, 7 Mcgill J. L.
and Health 85 (2013). Supporters of broad consent contend that the practical dilemmas associated with re-
quiring re-consent of individual participants for new research uses of their material make broad consent nec-
essary:Margaret F.A. Otlowski,Tackling Legal Challenges Posed by Population Biobanks: reconceptualising Con-
sent Requirements, 20Med. LawRev. 191 (2012); StephanieMFullerton,Meeting the Governance Challenges of
Next-Generation Biorepository Research, 2 Sci. Translational Med. 15cm3 (2010).
56 Additionally, commercialization raises issues related to the work of oversight bodies. For example, if a public
biobank receives private funding, researcherswho are using that biobank’s resourcesmay be required to obtain
additional ethics approval. Inotherwords, the involvementof aprivate entitymaybeenough to trigger theneed
for a reappraisal by an ethics review board. It is worth nothing that biobanks that are completely privately held
(such as biobanks created by pharmaceutical companies) can gounder the ethics review radar completely.This
may create concerns about whether appropriate ethics oversight mechanisms are in place to deal adequately
with a variety of commercialization-related concerns (eg if industry partnerships involve the use or merging of
datasets).
57 Caulfield, supra note 28.
58 Onora O’Neill, Some Limits of Informed Consent, 29 J. Med. Ethics 4 (2003).
59 Kieran C. O’Doherty et al., From Consent to Institutions: designing Adaptive Governance for Genomic Biobanks,
73 Soc. Sci. Med. 367 (2011).
60 Bartha Maria Knoppers and Ruth Chadwick,Human Genetic Research: Emerging Trends in Ethics, 6 Nat. Rev.
Genet. 75 (2005).
61 TRUDOLEMMENS ANDLORI LUTHER,HUMANGENETICDATABANKS: FROMCONSENTTOCOMMERCIALIZATION:
AN OVERVIEW OF CURRENT CONCERNS AND CONUNDRUMS (Encyclopedia of Life Support Systems, 2010),
www.eolss.net.
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the involvement of private entities should be enhanced by appropriate, long-termover-
sight.
Ownership, Access, andControl
The law relating to ownership and control of human biological material varies in dif-
ferent countries, and, in some countries, remains unclear.62 In the United Kingdom,
while courts have accepted that donors have some property rights in tissue set aside for
future use, this right does not extend to tissue collected for research purposes.63 In the
United States, courts have consistently held that individuals do not retain ownership
of material donated for research.64 However, individuals may still exercise some de-
gree of control over biological materials, as they are able to withdraw from research.65
And the existing jurisprudence may be limited by the facts, making its application to
other situations uncertain.66 As a result, the law regarding ownership and control re-
mains unclear.67 In Canada, while courts have not decided the issue of ownership of
human biological material used in research, individuals have a common law right to
access and, likely, control their health information.68 In Estonia, donated samples are
owned by the institution overseeing the biobank.69 In Portugal, the participant owns
the donated samples.70 Iceland does not use the term ‘ownership’ in its treatment of
research samples.71
Additionally, survey research tells us that there is no consensus within the general
public regarding who owns human biological material taken, stored and used for re-
search. For instance, a survey of 1,201 Albertans revealed that 44.3% believed that the
institution owned the samples, 25.7% felt that those who donated the samples owned
them, 23.1% felt that the scientists owned the samples and 6.9% believed that the re-
search funder owned the samples.72
As a result of this diversity of positions and legal uncertainty in several jurisdictions,
many scholars have called for clarification on the proprietary rights (eg access, control)
62 Moore versus Regents of University of California, 793 P.2d 479, 51 Cal. 3d 120, 271 Cal. Rptr. 146 (1990);
Greenberg versus Miami Children’s Hospital Res. Inst., Inc., 264 F. Supp. 2d 1064 (S.D. Fla. 2003);
Washington University versus Catalona, 490 F.3d 667 (8th Cir. 2007); National Health and Medical
Research Council, Biobanks Information Paper (2010), http://www.nhmrc.gov.au/ files nhmrc/file/
your health/egenetics/practioners/biobanks information paper.pdf; Timothy Caulfield and Amy L.
McGuire, Policy Uncertainty, Sequencing, and Cell Lines, 3 G3 (Bethesda) 1205 (2013). Altao Charo, Body
of Research—Ownership and Use of Human Tissue, 355.15 New Eng. J. Med. 1517 (2006). See also Capron,
supra note 30.
63 Yearworth versus North Bristol NHS Trust, 2009 E.W.C.A. Civ 37 (2009).
64 Moore, supra note 63; Greenberg, supra note 63; Catalona, supra note 63; Caulfield andMcGuire, supra note
63.
65 Caulfield andMcGuire, supra note 63; Catalona, 490 F.3d 667.
66 Charo, supra note 63.
67 Id. at 1517 (‘US jurisprudence still has no coherent answer to a deceptively simple question: Do we own our
own bodies?’).
68 McInerney versusMacDonald, 1992 S.C.R.2 138, 93 D.L.R. (4th) 415 (1992); Caulfield andMcGuire, supra
note 63.
69 Human Genes Research Act, RT I 2000, 104, 685, § 15.
70 Personal Genetic Information and Health Information Act, Law no. 12/2005 of 26 January, § 18.
71 Biobanks Act, No. 110/2000, § 10.
72 Caulfield et al., supra note 18.
106  A review of the key issues associated with the commercialization of biobanks
of donors, biobanks and researchers.73 The involvement of private entities in a public
biobank, and a concomitant need to understand who controls samples, seems likely to
make clarification even more imperative.
Sustainability andBankruptcy
Biobanks are expensive to maintain.74 A lack of sufficient funding may have a dramatic
impact on sustainability and raise challenging policy issues. Two recent bankruptcies
of private population biobanks, Genizon in Que´bec, Canada and deCODE Genetics
in Iceland, illustrate the ethical and policy dimensions of the issues raised in this con-
text. Both biobanks were privately owned and recruited their participants from homo-
geneous population groups originating in geographically determined locations.75
Given these similarities, it is interesting tonote thedifferent outcomesof bankruptcy
in the two cases. deCODE (with 140,000 samples from the Icelandic population) first
declared bankruptcy in 2009, selling its assets (including its biobank) to Saga Invest-
ments LCC. Saga is a group comprising some of the original investors in deCODEwho
kept running the company with a similar management structure. Following an unsuc-
cessful attempt to pierce the direct-to-consumer (DTC) market, the company was ac-
quired by the biotechnology giant Amgen for US$415million.76 So far, the sale has not
affected the management and objectives of the biobank, which remains located in Ice-
land.77 As part of the deCODE licence, the government required that the biobank stay
in Iceland, even if third parties became involved. However, Amgen has not offered any
written guarantee that this arrangementwill prevail over time and no court decision has
been rendered to that effect. Genizon (with 50,000 samples from the French Que´bec
founder population) was a Que´bec-based private biotechnology company in the busi-
ness of mapping and identifying genes for complex disorders. It filed for bankruptcy
and liquidated its tangible assets, excluding the biobank, in 2011.78 Later that year, the
Superior Court ofQue´becmandatedGe´nomeQue´bec (GQ), a provincial public fund-
ing agency, to act as the trustee of the biobank. In late 2012, GenomeQue´bec launched
a call for tenders with the hope of transferring Genizon’s biobank to aQue´bec research
centre.79 Following the closure of the call for tenders, Genome Quebec turned down
73 de Faria, Paula Lobato,Ownership Rights in Research Biobanks: doWe Need a New Kind of ‘Biological Property’?
inThe Ethics of Research Biobanking 263 (Springer 2009); Pilar N. Ossorio,TheHuman Genome as Common
Heritage: common Sense or Legal Nonsense?, 35 J. LawMed. Ethics 425 (2007); Tania Bubela et al.,Commercial-
ization andCollaboration: competing Policies in Publicly Funded StemCell Research?, 7 Cell StemCell 25 (2010);
Saminda Pathmasiri et al., Intellectual Property Rights in Publicly Funded Biobanks: much Ado About Nothing?,
29 Nat. Biotechnol. 319 (2011).
74 Jimmie Vaught et al., Biobankonomics: developing a Sustainable Business Model Approach for the Formation of a
Human Tissue Biobank, 2011 J. Natl. Cancer Inst. Monographs 24 (2011); Martin Yuille et al.,The UK DNA
Banking Network: a ‘Fair Access’ Biobank, 11 Cell Tissue Bank 241 (2010).
75 Jocelyn Kaiser, Human Genetics. Cash-Starved deCODE is Looking for a Rescuer for Its Biobank, 325 Science
1054 (2009); Kevin Davies, Quebec’s Genizon Biosciences Closes Its Doors (proposed 7 September 2011)
http://www.bio-itworld.com/news/09/07/2011/Quebec-Genizon-Biosciences-closes-doors.html.
76 Dan Vorhaus, Implications of Amgen/deCODE Deal for Genetic Testing Consumers, Genomics Law Re-
port (proposed 10 December 2012) http://www.genomicslawreport.com/index.php/2012/12/10/
implications-of-amgendecode-deal-for-genetic-testing-consumers/.
77 Monya Baker, Big Biotech Buys Iconic Genetics Firm, 492 Nature 321 (2012).
78 Davies, supra note 76.
79 Ge´nome Que´bec, Public Notice: genizon Biosciences Inc. (proposed 12 December 2012)
http://www.genomequebec.com/81-en.news-public-notice-genizon-biosciences-inc-.html.
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two valid bids by public groups deciding instead that it would continue managing the
Genizon biobank by itself.80
In cases like this, what should happen to the samples and data of the participants?
Can they be sold like other types ofmaterial assets?Transferred to another country?Or
should they be destroyed instead?Responses to these questions could have far reaching
implications for participants’ privacy, autonomy and dignity. In the case of bankruptcy,
the biobank’s policies, especially those regarding data privacy and data sharing, are rel-
evant for courts to determine the extent of what can be done with the participants’ data
and samples. The informed consent form signed by the participants will also play an
important role in that respect, by creating conditions that should be respected post-
bankruptcy. In this type of bankruptcy cases, US experts have alluded to the possibility
of legally appointing a Consumer Privacy Ombudsman (CPO) to assist the court on
privacy aspects of the process.81 However, to require this special procedure, the pro-
posed liquidation should meet strict criteria that likely would not apply to most cases
involving genomic biobanks.82 Given the sensitive nature of medical data, including
genetic data and tissue samples, and the importance of preserving public trust in sci-
ence, it appears that clear policies are required. Those policies should give weight to
the promises made to research participants at the inception of a biobank and ensure
more predictable outcomes in case of bankruptcy. However, developing such policies
may be challenging, as issues relating to bankruptcy or biobank closure are rarely pri-
orities at the inception of a biobank project83 and tend to be considered only in times
of hardship.
Access Agreements
To protect the professional interests of scientists and the rights of research partici-
pants, biobanks are increasingly making use of a variety of access agreements. Usu-
ally some of the data from the biobank (eg summary reads, genotype frequencies, a
limited amount of de-identified clinical data annotation fields) will be made available
openly while the more sensitive data (eg gene expression data, raw genotypes, specific
demographic data) and samples, if accessible at all, will be made available only to re-
searcherswhoagree to complywith the termsof these access agreements.84This second
mode of access is usually referred to as ‘controlled access’ or ‘managed access’ by the re-
search community. A biobank access committee will usually have the responsibility of
reviewing these access agreements and granting access to approved users. An intrinsic
80 Personal communication from Catalina Lopez-Correa, CSO, Genome Quebec (proposed 21 June 2013), on
file.
81 Dan Vorhaus and Lawrence Moore, What Happens If a DTC Genomics Company Goes Belly Up?,
Genomics Law Report (proposed 18 September 2009) http://www.genomicslawreport.com/index.php/
2009/09/18/what-happens-if-a-dtc-genomics-company-goes-belly-up/.
82 Id.; Ma’n H. Zawati et al., Closure of Population Biobanks and Direct-to-Consumer Genetic Testing Companies,
130 Hum. Genet. 425 (2011).
83 Cadigan, supra note 3, at 5–7.
84 International Cancer Genome Consortium (ICGC), International Cancer Genome Consortium
(ICGC) Goals, Structure, Policies and Guidelines (proposed 8 June 2010) http://icgc.org/icgc/
goals-structure-policies-guidelines; International Human Epigenome Consortium (IHEC), Goals,
Structure, Policies and Guidelines (proposed 10 January 2013) http://ihec-epigenomes.org/no cache/
about/policies-and-guidelines/?cid=52&did=11&sechash=c3c24f76.
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limitation of any current access agreement is the limited capacity of biobanks to effec-
tively monitor compliance and sanction potential infringers.85
Access agreements offer important advantages to biobanks but can also generate
substantial issues which the biobanks should strive to minimize. The current speed
of progress in informatics and bioinformatics has made it increasingly possible to re-
identify individuals from a small amount of genetic and/or clinical data and a match-
ing database, limiting the effectiveness of traditional means of protecting the identity
of research participants in open biobank projects (eg anonymization, coding, and de-
identification).86 Given this reality, it seems prudent to add another layer of protection
that does not solely rely on technology.
However, it should be recognized that the imposition of an access agreement
severely limits the open science nature of a biobank. Even the simplest access agree-
ment containing a minimal number of restrictions may deter a substantial number of
scientists fromapplying.87 Similarly, agreements that restrict access to or dissemination
of research datamay undermine the free flow of scientific knowledge. An important re-
lated issue is the risk that some biobanks, in an attempt tomeet their obligations to pro-
tect the rights of participants, will impose overly restrictive or unacceptable conditions
on members of the scientific community. Clauses requiring users to sign collaboration
agreements with biobanks, to agree to overly long moratorium periods before using
the data, to return enriched data to the biobank, or to give a first right of refusal on po-
tential emerging intellectual property are all examples of provisions that could severely
limit the open science nature of a biobank. Requiring an unacceptably high amount of
money as compensation for the provision of samples (under the pretense of cost re-
covery) would have a similar effect and could also be considered a commercial sale of
the human samples, which is illegal in many jurisdictions.88 This potential for misusing
access agreements should be recognized89 and biobank administrators should be care-
ful to use these agreements in a way that will only minimally restrict open science for
the real benefit of research participants. Therefore, the publication of consensus state-
ments or harmonized models of acceptable clauses for access agreements might have
a very positive impact on the current practices of biobanks.90 However, in some cases,
uniform policiesmay not address the unique circumstances of a particular biobank and
thus context-specific clauses will be preferable.
85 Yann Joly et al., Genomic Databases Access Agreements: legal Validity and Possible Sanctions, 130 Hum. Genet.
441 (2011). Compliance mechanisms should be in place before access is allowed, in order to ensure ethical
obligations are being met.
86 CatherineHeeney et al.,Assessing the Privacy Risks of Data Sharing in Genomics, 14 Public HealthGenomics 17
(2011).
87 DovGreenbaumet al.,Genomics and Privacy: Implications of theNewReality of ClosedData for the Field, 7 PLOS
Comput. Biol. e1002278 (2011); Yann Joly et al.,Data Sharing in the Post-GenomicWorld: the Experience of the
International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO), 8 PLOS Comput.
Biol. e1002549 (2012).
88 Peter H.J. Riegman et al., Biobanking for Better Healthcare, 2 Mol. Oncol. 213 (2008); Kathinka Evers et al.,
What Are Your Views on Commercialization of Tissues for Research? 10 Biopreserv. and Biobank. 476 (2012).
89 Disagreements over these terms are common in contractual arrangements between industry and academia,
and are not unique to the biobanking context.
90 See Capron, supra note 30.
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CONCLUSION
In addition to the issues examined above, introducing private funding into previously
publicly-fundedbiobanksmay exacerbate a range of other ethical issues.91 For example,
how to recognize the right to withdraw from research in the context of biobanking is a
controversialmatter.92The introduction of private entities or fundingmay further com-
plicate thewithdrawal issue because itmay create obligations on scientists to share data
with certain parties, including private partners, and data disseminated to themmay be
impossible to recall if a participant withdraws from the study.93 Similarly, the involve-
mentof private fundersmayexacerbateprivacy issuesor increase tensions related topri-
vacy. While funding itself is likely not an issue per se, if biological material and data are
shared with, for example, pharmaceutical companies, participants may feel as though
their privacy has been violated, which, as discussed above, may negatively impact pub-
lic trust in biobanks.94 Finally, the proliferation of biobanks around theworld and other
technological innovations are increasinglymaking possible wide-spread sharing of data
and biological samples, a practice which is encouraged in order to realize the economic
and scientific potential of biobanks.95 This practice may be impacted or hindered by
the introduction of private funding and collaboration with private entities, as the ex-
pectations of private entities and agreements governing such partnerships may create
sharing barriers. Efforts to develop harmonized policies and interoperability between
biobanks may address some of the issues that arise in this regard.96
Because biobanks are costly to develop and maintain, biobank developers are look-
ing to private investment to facilitate the long-term sustainability of these important
research tools. In addition, increased pressures to commercialize—now ubiquitous in
the policies of public funding agencies and universities—have encouraged biobanks to
partner with private entities. While these kinds of partnerships are often necessary and
can facilitate the translationof useful technologies andpractices, the commercialization
91 The handling of incidental findings (IFs) has emerged as one of the most contentious issues in the area of
biobanking. See, for example, S.M. Wolf, B.N. Crock, B. Van Ness, et al., ‘Managing incidental findings and
research results in genomic research involving biobanks and archived datasets’ 14 Genet. Med. 361 (2012). We
have not addressed this topic, as it is not closely related to the commercialization process. However, it should
be noted that even this issuemaybe complicated by the involvement of industry as this invitesmore individuals
(ie those in industry) to become aware of IFs.
92 Kristina Hug et al.,Withdrawal from Biobank Research: considerations and the Way Forward, 8 Stem Cell Rev.
1056 (2012); Stefan Eriksson andGert Helgesson, Potential Harms, Anonymization, and the Right toWithdraw
Consent to Biobank Research, 13 Eur. J. Hum. Genet. 1071 (2005).
93 Timothy Caulfield et al., Research Ethics Recommendations for Whole-Genome Research: consensus Statement, 6
PLOS Biol. e73 (2008).
94 Critchley et al., supra note 17.
95 Knoppers et al., supra note 2. Wylie Burke et al., Extending the Reach of Public Health Genomics: what Should
Be the Agenda for Public Health in an Era of Genome-Based and ‘personalized’ Medicine?, 12 Genet. Med. 785
(2010); Eric M. Meslin and Ibrahim Garba, Biobanking and Public Health: is a Human Rights Approach the
Tie that Binds?, 130 Hum. Genet. 451 (2011); Stacey Periera, Motivations and Barriers to Sharing Biologi-
cal Samples: a Case Study, 3 J. Pers. Med. 102 (2013); H3Africa | Homepage (proposed 16 August 2013)
http://www.h3africa.org/.
96 Bartha M Knoppers and Rosario Isasi, Stem Cell Banking: between Traceability and Identifiability, 2 Genome
Med. 73 (2010); Creating a Global Alliance to Enable Responsible Sharing of Genomic and Clinical Data
http://oicr.on.ca/globalalliance.
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of biobanks also raises a host of issues that should be considered in both the develop-
ment of these partnerships and relevant policy, including:
 The potential to adversely impact the public trust;
 Consent challenges, such as the possible requirement to obtain re-consent;
 Exacerbating privacy issues and with the possible requirement for additional
oversight or mechanisms to protect participants’ privacy;
 Challenges for oversight bodies, such as research ethics boards, in monitoring
research;
 Possible tensions regarding the ownership and sharing of biological samples
and data; and
 Uncertainty concerning the use and control of the resource if biobanks go
bankrupt or lose funding support.
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